Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma

Publish date:: August 12, 2020

Key clinical point: Elotuzumab-based maintenance may deepen response post transplant in MM.

Major finding: There was a combined complete response (CR) or very good partial response (VGPR) rate increase from 57.1% to 100% (CR = 3, VGPR = 4).

Study details: Retrospective evaluation of seven MM patients who were started on elotuzumab-based maintenance after transplant.

Disclosures: The study did not receive outside funding and the researchers reported that they had no disclosures.

Citation:

Wang X et al. Blood Cells Mol Dis. 2020 Jul 28. doi: 10.1016/j.bcmd.2020.102482.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lymphoma & Plasma Cell Disorders

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,